Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
What Are the Projected Market Size and Growth Rates for the Pulmonary Drugs Market From 2025 To 2029?
The market size for pulmonary drugs has seen significant growth in the past few years. The market, valued at $54.28 billion in 2024, is predicted to increase to $57.53 billion in 2025, indicative of a compound annual growth rate (CAGR) of 6.0%. This notable increase during the historical period can be tied to several factors such as the increased occurrence of respiratory diseases, the escalation in smoking rates, a growing elderly population, wider healthcare availability, and a spike in pollution levels.
In the upcoming years, the size of the pulmonary drugs market is projected to experience robust growth, escalating to $71.91 billion by 2029 with a compound annual growth rate (CAGR) of 5.7%. The expansion within the forecast period is likely due to the advancement of healthcare facilities, the increased incidence of cardiovascular diseases, the augmentation of homecare therapies, the growing consciousness about lung diseases, and the prominence of asthma. Foreseen trends for the period include progress in technology, drug discovery facilitated by AI, utilization of smart inhalers, formulation based on nanotechnology, and progress in gene therapy.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp
What are the Fundamental Drivers and Innovations Shaping the Pulmonary Drugs Market?
The escalating incidence of respiratory conditions is likely to stimulate the expansion of the pulmonary drugs market in the future. Respiratory disorders, which impact the lungs and airways, disrupt usual breathing and the exchange of oxygen. The rise in such disorders is a result of increased smoking, which contributes to lung damage and chronic illnesses. Pulmonary medications are essential in controlling these disorders by enhancing lung performance, mitigating inflammation, and alleviating blocked airways for improved respiration. For example, the Bureau of Labor Statistics, a governmental agency in the United States, reported that the disease rate among private industry employers amplified to 45.2 cases per 10,000 FTE employees in 2022, a surge from 37.7 cases in 2021. This increase was primarily due to a heightened frequency of respiratory ailments, which expanded from 27.8 cases per 10,000 FTE employees in 2021 to 35.8 cases the following year. Thus, the proliferation of respiratory diseases is fuelling the growth of the pulmonary drugs market.
How Is the Pulmonary Drugs Market Segmented?
The pulmonary drugs market covered in this report is segmented –
1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes
2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications
3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies
Subsegments:
1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide
2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol
3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine
4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues
5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol
6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp
Which Regions Are Driving the Next Phase of the Pulmonary Drugs Market Growth?
North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Pulmonary Drugs Market?
Leading firms in the pulmonary drugs market are concentrating on the creation of novel therapies like single-inhaler triple therapy (SITT) to boost treatment effectiveness, augment patient compliance, and make medication schedules easier for superior disease control. The SITT treatment amalgamates three varied medicines in one inhaler to deal with chronic respiratory illnesses, for example, chronic obstructive pulmonary disease (COPD), more efficiently. For example, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, a pharmaceutical firm based in India, released Trelegy Ellipta, the first of its kind single-inhaler triple therapy (SITT) in India for COPD patients. This therapeutic approach merges fluticasone furoate, umeclidinium, and vilanterol to enhance pulmonary functionality and diminish symptom flare-ups. The advanced Ellipta inhaler guarantees accurate dosage and boosts patient adherence compared to numerous inhaler therapies. Given that India has over 100 million COPD patients, this introduction aims to streamline therapy and enhance patient results.
View the full report here:
https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report
How Is the Pulmonary Drugs Market Defined and What Are Its Core Parameters?
Pulmonary drugs refer to medications that target the respiratory system to improve lung function, reduce inflammation, and manage airway disorders. They are used for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23489
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model